Breaking News Instant updates and real-time market news.

CRBP

Corbus Pharmaceuticals

$7.00

-0.05 (-0.71%)

08:36
10/19/17
10/19
08:36
10/19/17
08:36

Technical View: Corbus Pharmaceuticals surges on anabasum Phase 2 results

The stock was last up over 17% in the pre-market to $8.20, on heavy volume. At that price next resistance is at $8.60 and then at the $9 area. Support is at the $8 area.

CRBP Corbus Pharmaceuticals
$7.00

-0.05 (-0.71%)

09/29/17
09/29/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Regeneron (REGN) assumed with an Overweight at Piper Jaffray. 2. MasterCard (MA) and Visa (V) were initiated with an Overweight at Cantor Fitzgerald. 3. Liberty Global (LBTYA, LBTYK) and Liberty Global LiLAC (LILA) were initiated with a Buy at Buckingham. 4. Corbus Pharmaceuticals (CRBP) coverage assumed with a Buy at Noble Financial. 5. Medpace (MEDP) initiated with a Market Perform at Raymond James. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/29/17
NBLE
09/29/17
INITIATION
NBLE
Buy
Corbus Pharmaceuticals coverage assumed with a Buy at Noble Financial
Noble Financial analyst Caroline Palomeque assumed coverage of Corbus with a $16 price target and a Buy rating. The analyst believes that the launch of several trials of the company's Anabasum drug and the announcement of data on the drug from several other trials will be positive catalysts for the stock.
09/20/17
CANT
09/20/17
NO CHANGE
Target $24
CANT
Overweight
Corbus data 'encouraging supportive' for prior study, says Cantor
Cantor Fitzgerald analyst Elemer Piros reiterates an Overweight rating and $24 price target on Corbus Pharmaceuticals, following release of abstracts from the American College of Rheumatology meeting scheduled for November 3-8. Previously placebo-treated patients in one abstract began to demonstrate a meaningful response when treated with anabasum, while previously treated anabasum patients continued to improve response, Piros tells investors in a research note. He views these data as "encouraging supportive" for the prior Phase 2 study.
05/09/17
CANT
05/09/17
NO CHANGE
Target $24
CANT
Corbus poised to enter late stage development in 2017, says Cantor
Cantor Fitzgerald analyst Elemer Piros reiterates an Overweight rating and $24 price target on Corbus Pharmaceuticals' following its Q1 report, stating that the company is poised to enter late stage development in 2017 and noting that anabasum has fast track status and is eligible for priority review and submission through a rolling NDA.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

14:17
11/21/17
11/21
14:17
11/21/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
11/21/17
11/21
14:16
11/21/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSK

GlaxoSmithKline

$34.91

-0.21 (-0.60%)

, PFE

Pfizer

$35.61

0.2648 (0.75%)

14:05
11/21/17
11/21
14:05
11/21/17
14:05
Hot Stocks
FDA approves ViiV Healthcare's two drug HIV treatment Juluca »

The FDA today said it…

GSK

GlaxoSmithKline

$34.91

-0.21 (-0.60%)

PFE

Pfizer

$35.61

0.2648 (0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 07

    Dec

  • 14

    Dec

OCLR

Oclaro

$6.49

-0.09 (-1.37%)

14:05
11/21/17
11/21
14:05
11/21/17
14:05
Options
Oclaro call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

  • 12

    Dec

NUE

Nucor

$56.02

0.46 (0.83%)

14:04
11/21/17
11/21
14:04
11/21/17
14:04
Hot Stocks
Nucor announces plans to build rebar micro mill »

Nucor announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTK

Cytokinetics

$11.10

-0.7 (-5.93%)

14:01
11/21/17
11/21
14:01
11/21/17
14:01
Recommendations
Cytokinetics analyst commentary  »

Cytokinetics price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CYTK

Cytokinetics

$11.10

-0.7 (-5.93%)

13:59
11/21/17
11/21
13:59
11/21/17
13:59
Recommendations
Cytokinetics analyst commentary  »

Cytokinetics price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

SSNLF

Samsung

, WHR

Whirlpool

$166.91

1.71 (1.04%)

13:58
11/21/17
11/21
13:58
11/21/17
13:58
Periodicals
ITC calls for tariff-rate quota on imported Samsung, LG washers, Reuters says »

The U.S. International…

SSNLF

Samsung

WHR

Whirlpool

$166.91

1.71 (1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RF

Regions Financial

$15.70

-0.16 (-1.01%)

13:55
11/21/17
11/21
13:55
11/21/17
13:55
Options
Regions Financial put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLMT

Calumet Specialty Products

$8.30

0.1 (1.22%)

13:53
11/21/17
11/21
13:53
11/21/17
13:53
Hot Stocks
Calumet Specialty Products announces divestiture of Anchor Drilling Fluids »

Calumet Specialty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITUS

ITUS

$3.16

0.25 (8.59%)

13:53
11/21/17
11/21
13:53
11/21/17
13:53
Conference/Events
ITUS to hold a pharmaceutical update conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENBL

Enable Midstream

$15.03

-0.0315 (-0.21%)

13:49
11/21/17
11/21
13:49
11/21/17
13:49
Downgrade
Enable Midstream rating change  »

Enable Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STLY

Stanley Furniture

$0.93

0.0349 (3.92%)

13:47
11/21/17
11/21
13:47
11/21/17
13:47
Hot Stocks
Stanley Furniture to sell substantially all its assets »

As previously reported,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:40
11/21/17
11/21
13:40
11/21/17
13:40
General news
NY Fed's overnight reverse repo totaled $42.9 B (19 counterparties) »

NY Fed's overnight…

EYE

National Vision

$30.19

0.21 (0.70%)

13:33
11/21/17
11/21
13:33
11/21/17
13:33
Initiation
National Vision initiated  »

National Vision initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CYTK

Cytokinetics

$11.10

-0.7 (-5.93%)

13:32
11/21/17
11/21
13:32
11/21/17
13:32
Downgrade
Cytokinetics rating change  »

Cytokinetics downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

LOW

Lowe's

$81.59

0.13 (0.16%)

13:27
11/21/17
11/21
13:27
11/21/17
13:27
Recommendations
Lowe's analyst commentary  »

Lowe's price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

WHR

Whirlpool

$165.67

0.47 (0.28%)

13:25
11/21/17
11/21
13:25
11/21/17
13:25
Periodicals
ITC suggests tariffs on washing machine imports above 1.2M units, Bloomberg says »

Two of four ITC officials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWI

Armstrong World

$53.70

-0.15 (-0.28%)

13:25
11/21/17
11/21
13:25
11/21/17
13:25
Conference/Events
Armstrong World to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

BMO

Bank of Montreal

$77.39

0.06 (0.08%)

13:21
11/21/17
11/21
13:21
11/21/17
13:21
Hot Stocks
BMO Financial Group enters partnership with CDL-Montreal »

BMO Financial Group and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:20
11/21/17
11/21
13:20
11/21/17
13:20
General news
Fed Governor Powell's hearings for the position as Fed Chair »

Fed Governor…

PG

Procter & Gamble

$88.93

0.66 (0.75%)

13:20
11/21/17
11/21
13:20
11/21/17
13:20
Options
Buyer lays out 500K for three month upside in Procter and Gamble »

Buyer lays out 500K for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

13:17
11/21/17
11/21
13:17
11/21/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
11/21/17
11/21
13:16
11/21/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$49.71

-0.21 (-0.42%)

13:05
11/21/17
11/21
13:05
11/21/17
13:05
Options
CSX call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.